Pelthos Therapeutics Inc (PTHS)
Pelthos Therapeutics Inc. is a biotechnology company listed on the NYSE under the ticker PTHS. The company develops and commercializes therapeutic products aimed at addressing conditions with significant unmet treatment needs. Its marketed products include ZELSUVMI, used for molluscum contagiosum in adults and children aged one year and older; XEPI (ozenoxacin) cream, an antimicrobial treatment for impetigo in adult and pediatric patients two months of age and older; and XEGLYZE, a topical treatment for head lice infestation in patients six months of age and older. Pelthos also develops NITRICIL, its proprietary nitric oxide-based technology platform. The company, previously known as Channel Therapeutics Corporation, adopted the Pelthos Therapeutics name in July 2025 and is based in Durham, North Carolina.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-PTHS
|
$31.78
|
20.8% Upside
|
Undervalued
|
$57.71
|
119.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 24, 2026
|
-1.8x
|
2.6x
|
3.3x
|
94.746 M
|
112.4 M
|
35.8%
|
40.1%
|
-1.5
|
—
|
68.6%
|
